Hubbry Logo
Zinc deficiencyZinc deficiencyMain
Open search
Zinc deficiency
Community hub
Zinc deficiency
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Zinc deficiency
Zinc deficiency
Zinc deficiency
View on Wikipedia
from Wikipedia

Zinc deficiency
Zinc
SpecialtyEndocrinology Edit this on Wikidata
Causesa diet high in phytate-containing whole grains

Zinc deficiency is defined either as insufficient body levels of zinc to meet the needs of the body, or as a zinc blood level below the normal range.[1][2][3] However, since a decrease in blood concentration is only detectable after long-term or severe depletion, blood levels of zinc are not a reliable biomarker for zinc status.[4] Common symptoms include increased rates of diarrhea. Zinc deficiency affects the skin and gastrointestinal tract; brain and central nervous system, immune, skeletal, and reproductive systems.[2][3]

Zinc deficiency in humans is caused by reduced dietary intake, inadequate absorption, increased loss, or increased body system use.[3] The most common cause is reduced dietary intake. In the U.S., the Recommended Dietary Allowance (RDA) is 8 mg/day for women and 11 mg/day for men.[5]

The highest concentration of dietary zinc is found in oysters, meat, beans, and nuts.[1] Increasing the amount of zinc in the soil and thus in crops and animals is an effective preventive measure. Zinc deficiency may affect up to 17% or 2 billion people worldwide.[2][6]

Signs and symptoms

[edit]

Skin, nails, and hair

[edit]

Zinc deficiency may manifest as acne,[7] eczema, xerosis (dry, scaling skin), seborrheic dermatitis,[8] or alopecia (thin and sparse hair).[8][9] It may also impair or possibly prevent wound healing.[9]

Mouth

[edit]

Zinc deficiency can manifest as non-specific oral ulceration, stomatitis, or white tongue coating.[8] Rarely it can cause angular cheilitis (sores at the corners of the mouth).[10]

Vision, smell, and taste

[edit]

Severe zinc deficiency may disturb the sense of smell[9] and taste.[11][12][13] Night-blindness may be a feature of severe zinc deficiency,[9] although most reports of night-blindness and abnormal dark adaptation in humans with zinc deficiency have occurred in combination with other nutritional deficiencies (e.g., vitamin A).[14]

Immune system

[edit]

Impaired immune function in people with zinc deficiency can lead to the development of respiratory, gastrointestinal, or other infections, e.g., pneumonia.[9][15][16] The levels of inflammatory cytokines (e.g., IL-1β, IL-2, IL-6, and TNF-α) in blood plasma are affected by zinc deficiency and zinc supplementation produces a dose-dependent response in the level of these cytokines.[17] During inflammation, there is an increased cellular demand for zinc, and impaired zinc homeostasis from zinc deficiency is associated with chronic inflammation.[17]

Diarrhea

[edit]

Zinc deficiency contributes to an increased incidence and severity of diarrhea.[15][16]

Appetite

[edit]

Zinc deficiency may lead to loss of appetite.[18]

Cognitive function and hedonic tone

[edit]

Cognitive functions, such as learning and hedonic tone, are impaired with zinc deficiency.[6][19] Moderate and more severe zinc deficiencies are associated with behavioral abnormalities, such as irritability, lethargy, and depression (e.g., involving anhedonia).[20] Zinc supplementation produces a rapid and dramatic improvement in hedonic tone (i.e., general level of happiness or pleasure) under these circumstances.[20] Zinc supplementation has been reported to improve symptoms of ADHD and depression.[6][21][22]

Psychological disorders

[edit]

Low plasma zinc levels have been alleged to be associated with many psychological disorders. Schizophrenia has been linked to decreased brain zinc levels.[23] Evidence suggests that zinc deficiency could play a role in depression.[23][24][25] Zinc supplementation may be an effective treatment in major depression.[26][27]

Growth

[edit]

Zinc deficiency in children can cause delayed growth[8] and has been claimed to cause stunted growth in one-third of the world's population.[28]

During pregnancy

[edit]

Zinc deficiency during pregnancy can negatively affect both the mother and fetus. Animal studies indicate that maternal zinc deficiency can upset the sequencing and efficiency of the birth process. An increased incidence of difficult and prolonged labor, hemorrhage, uterine dystocia, and placental abruption has been documented in zinc-deficient animals.[29] The defective functioning of estrogen may mediate these effects via the estrogen receptor, which contains a zinc finger protein.[29] A review of pregnancy outcomes in women with acrodermatitis enteropathica, reported that out of every seven pregnancies, there was one abortion and two malfunctions, suggesting the human fetus is also susceptible to the teratogenic effects of severe zinc deficiency. However, a review of zinc supplementation trials during pregnancy did not report a significant effect of zinc supplementation on neonatal survival.[29]

Zinc deficiency can interfere with many metabolic processes during infancy and childhood, a time of rapid growth and development when nutritional needs are high.[30] Low maternal zinc status has been associated with less attention during the neonatal period and worse motor functioning.[31] In some studies, supplementation has been associated with motor development in very low birth weight infants and more vigorous and functional activity in infants and toddlers.[31]

Testosterone production

[edit]

Zinc is required to produce testosterone. Thus, zinc deficiency can lead to reduced circulating testosterone, which could lead to sexual immaturity, hypogonadism, and delayed puberty.[8]

Causes

[edit]

Dietary deficiency

[edit]
Oysters contain a high amount of zinc.

Zinc deficiency can be caused by a diet high in phytate-containing whole grains, foods grown in zinc-deficient soil, or processed foods containing little or no zinc.[32][33] Conservative estimates suggest that 25% of the world's population is at risk of zinc deficiency.[34]

In the U.S., the Recommended Dietary Allowance (RDA) is 8 mg/day for women and 11 mg/day for men. RDA for pregnancy is 11 mg/day. RDA for lactation is 12 mg/day. For infants up to 12 months, the RDA is 3 mg/day. For children ages 1–13 years the RDA increases with age from 3 to 8 mg/day.[5] The following table summarizes most of the foods with significant quantities of zinc, listed in order of quantity per serving, unfortified.[1] Note that the top 10 entries are meat, beans, or nuts.

Food mg in one serving Percentage of 11 mg recommended daily intake
Oysters, cooked, breaded, and fried, 3 ounces (85 g) (about 5 average-sized oysters) 74.0 673%
Beef chuck roast, braised, 3 ounces (85 g) 7.0 64%
Crab, Alaska king, cooked, 3 ounces (85 g) 6.5 59%
Beef patty, broiled, 3 ounces (85 g) 5.3 48%
Cashews, dry roasted, 3 ounces (85 g) 4.8 44%
Lobster, cooked, 3 ounces (85 g) 3.4 31%
Pork chop, loin, cooked, 3 ounces (85 g) 2.9 26%
Baked beans, canned, plain, or vegetarian, 1/2 cup (~120 mL) 2.9 26%
Almonds, dry roasted, 3 ounces (85 g) 2.7 25%
Chicken, dark meat, cooked, 3 ounces (85 g) 2.4 22%
Yogurt, fruit, low fat, 8 ounces (230 g) 1.7 15%
Shredded wheat, unfortified, 1 cup (~240 mL)[35] 1.5 14%
Chickpeas, cooked, 1/2 cup (~120 mL) 1.3 12%
Cheese, Swiss, 1 ounce (28 g) 1.2 11%
Oatmeal, instant, plain, prepared with water, 1 packet 1.1 10%
Milk, low-fat or non-fat, 1 cup (~240 mL) 1.0 9%
Kidney beans, cooked, 1/2 cup (~120 mL) 0.9 8%
Chicken breast, roasted, skin removed, 1⁄2 breast 0.9 8%
Cheese, cheddar, or mozzarella, 1 ounce (28 g) 0.9 8%
Peas, green, frozen, cooked, 1/2 cup (~120 mL) 0.5 5%
Flounder or sole, cooked, 3 ounces (85 g) 0.3 3%

Recent research findings suggest that increasing atmospheric carbon dioxide concentrations will exacerbate zinc deficiency problems in populations that consume grains and legumes as staple foods. A meta-analysis of data from 143 studies comparing the nutrient content of grasses and legumes grown in ambient and elevated CO2 environments found that the edible portions of wheat, rice, peas, and soybeans grown in elevated CO2 contained less zinc and iron.[36] Global atmospheric CO2 concentration is expected to reach 550 p.p.m. in the late 21st century. At this CO2 level the zinc content of these crops was 3.3–9.3% lower than that of crops grown in the present atmosphere. A model of the nutritional impact of these lower zinc quantities on the populations of 151 countries predicts that an additional 175 million people could face dietary zinc deficiency as the result of increasing atmospheric CO2.[37]

Inadequate absorption

[edit]

Acrodermatitis enteropathica is an inherited deficiency of the zinc transporter ZIP4 protein, resulting in inadequate zinc absorption.[9] It presents as retarded growth, severe diarrhea, hair loss, skin rash (most often around the genitalia and mouth) and opportunistic candidiasis, and bacterial infections.[9]

Numerous small bowel diseases which cause destruction or malfunction of the gut mucosa enterocytes and generalized malabsorption are associated with zinc deficiency.[2][3]

Increased loss

[edit]

Exercising, high alcohol intake, and diarrhea increase the body's loss of zinc.[8][38] Changes in intestinal tract absorbability and permeability due, in part, to viral, protozoal, or bacteria pathogens may also encourage fecal losses of zinc.[39]

Chronic disease

[edit]

The mechanism of zinc deficiency in some diseases has not been well defined; it may be multifactorial.[2]

Wilson's disease, sickle cell disease, chronic kidney disease, and chronic liver disease have all been associated with zinc deficiency.[40][41] It can also occur after bariatric surgery and exposure to mercury.[42][43]

Although marginal zinc deficiency is often found in depression, low zinc levels could either be a cause or a consequence of mental disorders and their symptoms.[24]

Mechanism

[edit]

As biosystems cannot store zinc, regular intake is necessary. Excessively low zinc intake can lead to zinc deficiency, negatively impacting an individual's health.[2][3][44] The mechanisms for the clinical manifestations of zinc deficiency are best appreciated by recognizing that zinc functions in the body in three areas: catalytic, structural, and regulatory.[5][45] Zinc (Zn) is only common in its +2 oxidative state, where it typically coordinates with tetrahedral geometry. It is important in maintaining basic cellular functions such as DNA replication, RNA transcription, cell division, and cell activations. However, having too much or too little zinc can compromise these functions.

Some 50 enzymes are dependent on zinc for their roles in catalysis.[3] In its structural role, zinc coordinates with certain protein domains, facilitating protein folding and producing structures such as 'zinc fingers'. In its regulatory role, zinc is involved in the activity of nucleoproteins and various inflammatory cells. For example, zinc regulates the expression of metallothionein, which has multiple functions, such as intracellular zinc compartmentalization[46] and antioxidant function.[47][48] Thus zinc deficiency results in disruption of hundreds of metabolic pathways, causing numerous clinical manifestations, including impaired growth and development, and disruption of reproductive and immune function.[8][49][50]

Pra1 (pH-regulated antigen 1) is a Candida albicans protein that scavenges host zinc.[51]

Diagnosis

[edit]

Diagnosis is typically made based on clinical suspicion and a low zinc level in the blood. Any level below 70 mcg/dL (normal 70-120 mcg/dL) is considered zinc deficiency. However there is a paucity of adequate zinc biomarkers, and the most widely used indicator, plasma zinc, has poor sensitivity and specificity.[52]

Zinc deficiency could be also associated with low alkaline phosphatase since it acts a cofactor for this enzyme.[2]

Classification

[edit]

Zinc deficiency can be classified as acute, as may occur during prolonged inappropriate zinc-free total parenteral nutrition; or chronic, as may occur in dietary deficiency or inadequate absorption.[28]

Prevention

[edit]
Zinc gluconate tablets
Zinc rich foods. Oysters, beef, peanuts, dark chicken meat

Five interventional strategies can be used:

  • Adding zinc to soil, called agronomic biofortification, which both increases crop yields and provides more dietary zinc.
  • Adding zinc to food, called food fortification. The Republic of China, India, Mexico, and about 20 other countries, mostly on the east coast of sub-Saharan Africa, fortify wheat flour and/or maize flour with zinc.[53]
  • Adding zinc-rich foods to the diet. The foods with the highest concentration of zinc are proteins, especially animal meats, the highest being oysters.[8] Per ounce, beef, pork, and lamb contain more zinc than fish. The dark meat of a chicken has more zinc than the light meat. Other good sources of zinc are nuts, whole grains, legumes, and yeast.[54] Although whole grains and cereals are high in zinc, they also contain chelating phytates which bind zinc and reduce its bioavailability.[8]
  • Oral repletion via tablets (e.g., zinc gluconate) or liquid (e.g., zinc acetate). Oral zinc supplementation in healthy infants more than six months old has been shown to reduce the duration of any subsequent diarrheal episodes by about 11 hours.[55]
  • Oral repletion via multivitamin/mineral supplements containing zinc gluconate, sulfate, or acetate. It is not clear whether one form is better than another.[54]

Epidemiology

[edit]

Zinc deficiency affects about 2.2 billion people around the world.[6] Severe zinc deficiency is rare and is mainly seen in persons with acrodermatitis enteropathica, a severe defect in zinc absorption due to a congenital deficiency in the zinc carrier protein ZIP4 in the enterocyte.[8] Mild zinc deficiency due to reduced dietary intake is common.[8] Conservative estimates suggest that 25% of the world's population is at risk of zinc deficiency.[34] Providing micronutrients, including zinc, to humans is one of the four solutions to major global problems identified in the Copenhagen Consensus from an international panel of economists.[56]

History

[edit]

Significant historical events related to zinc deficiency began in 1869 when zinc was first discovered to be essential to the growth of an organism Aspergillus niger.[57] In 1929 Lutz measured zinc in numerous human tissues using the dithizone technique and estimated total body zinc in a 70 kg man to be 2.2 grams. Zinc was found to be essential to the growth of rats in 1933.[58] In 1939 beriberi patients in China were noted to have decreased zinc levels in skin and nails. In 1940 zinc levels in a series of autopsies found it to be present in all tissues examined. In 1942 a study showed most zinc excretion was via the feces. In 1950 a normal serum zinc level was first defined and found to be 17.3–22.1 micromoles/liter. In 1956 cirrhotic patients were found to have low serum zinc levels. In 1963 zinc was determined to be essential to human growth, three enzymes requiring zinc as a cofactor were described, and a report was published of a 21-year-old Iranian man with stunted growth, infantile genitalia, and anemia which were all reversed by zinc supplementation.[59] In 1972 fifteen Iranian rejected army inductees with symptoms of zinc deficiency were reported: all responded to zinc. In 1973 the first case of acrodermatitis enteropathica due to severe zinc deficiency was described. In 1974 the National Academy of Sciences declared zinc to be an essential element for humans and established a recommended daily allowance. In 1978 the Food and Drug Administration required zinc to be in total parenteral nutrition fluids. In the 1990s there was increasing attention on the role of zinc deficiency in childhood morbidity and mortality in developing countries.[60] In 2002 the zinc transporter protein ZIP4 was first identified as the mechanism for absorption of zinc in the gut across the basolateral membrane of the enterocyte. By 2014 over 300 zinc-containing enzymes have been identified, as well as over 1000 zinc-containing transcription factors.[citation needed]

Phytate was recognized as removing zinc from nutrients given to chicken and swine in 1960. That it can cause human zinc deficiency however was not recognized until Reinhold's work in Iran in the 1970s. This phenomenon is central to the high risk of zinc deficiency worldwide.[61]

Soils and crops

[edit]
See also: Zinc deficiency (plant disorder)

Soil zinc is an essential micronutrient for crops. Almost half of the world's cereal crops are deficient in zinc, leading to poor crop yields.[62] Many agricultural countries around the world are affected by zinc deficiency.[63] In China, zinc deficiency occurs on around half of the agricultural soils, affecting mainly rice and maize. Areas with zinc-deficient soils are often regions with widespread zinc deficiency in humans. Basic knowledge of the dynamics of zinc in soils, an understanding of the uptake and transport of zinc in crops, and characterizing the response of crops to zinc deficiency are essential steps in achieving sustainable solutions to the problem of zinc deficiency in crops and humans.[64]

Biofortification

[edit]

Soil and foliar application of zinc fertilizer can effectively increase grain zinc and reduce the phytate-to-zinc ratio in grain.[65][66] People who eat bread prepared from zinc enriched wheat or fortified breakfast cereals have a significant increase in serum zinc.[3]

Zinc fertilization not only increases zinc content in zinc-deficient crops, it also increases crop yields.[64] Balanced crop nutrition supplying all essential nutrients, including zinc, is a cost-effective management strategy. Even with zinc-efficient varieties, zinc fertilizers are needed when the available zinc in the topsoil becomes depleted.

Plant breeding can improve the zinc uptake capacity of plants under soil conditions with low chemical availability of zinc. Breeding can also improve zinc translocation which elevates zinc content in edible crop parts as opposed to the rest of the plant.

Central Anatolia, in Turkey, was a region with zinc-deficient soils and widespread zinc deficiency in humans. In 1993, a research project found that yields could be increased by 6 to 8-fold and child nutrition dramatically increased through zinc fertilization.[67] Zinc was added to fertilizers. While the product was initially made available at the same cost, the results were so convincing that Turkish farmers significantly increased the use of the zinc-fortified fertilizer (1 percent of zinc) within a few years, despite the repricing of the products to reflect the added value of the content. Nearly ten years after the identification of the zinc deficiency problem, the total amount of zinc-containing compound fertilizers produced and applied in Turkey reached a record level of 300,000 tonnes per annum. It is estimated that the economic benefits associated with the application of zinc fertilizers on zinc-deficient soils in Turkey is around US$100 million per year. Zinc deficiency in children has been dramatically reduced.

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Zinc deficiency

View on Grokipedia
from Grokipedia
Zinc deficiency is a disorder arising from inadequate intake, absorption, or retention of , an essential serving as a cofactor in over 300 enzymes involved in , transcription, , and immune function. It manifests primarily through impaired growth and development in children, heightened susceptibility to infectious diseases due to compromised , and dermatological issues such as acrodermatitis-like rashes and alopecia. This deficiency contributes significantly to global morbidity, particularly in low-income populations dependent on diets high in unrefined cereals containing phytates that bind and reduce . Prevalent worldwide, zinc deficiency affects an estimated 17.3% of the global population at risk, with nearly 2 billion individuals impacted, disproportionately in developing regions where staple foods inhibit absorption and infectious diseases exacerbate losses through . In children under five, it underlies increased rates of stunting, , and diarrheal mortality, accounting for over 500,000 deaths annually, underscoring its role as a modifiable in undernutrition. Acquired forms stem from malabsorptive conditions like or chronic , while genetic disorders such as represent rare congenital causes. Correction of deficiency through supplementation or yields measurable improvements in and growth, yet challenges persist in due to nonspecific symptoms and variable plasma levels influenced by , highlighting the need for functional biomarkers beyond serum zinc concentrations. Emerging evidence links subclinical deficiency to broader burdens, including delayed , cognitive deficits, and heightened vulnerability to , emphasizing zinc's causal role in maintaining rather than mere association.

Definition and Classification

Definitions and diagnostic criteria

Zinc deficiency is characterized by inadequate zinc availability relative to physiological needs, impairing functions such as , , , and , as serves as a cofactor for over 300 enzymes. This condition arises when dietary intake, absorption, or retention fails to meet requirements, which vary by age, sex, and physiological state (e.g., or increases demand to 11-13 mg/day). Marginal deficiency, more common than overt cases, may not alter plasma levels but can still contribute to subtle functional deficits. Diagnosis is primarily clinical, supplemented by biochemical tests, due to the absence of a gold-standard ; presumptive diagnosis involves compatible symptoms alongside risk factors like or . Key clinical features include growth stunting in children, chronic , alopecia, acral or periorificial , impaired taste (), anorexia, and increased susceptibility to infections, with severe genetic forms (e.g., ) presenting neonatally with bullous pustular eruptions and . In adults, manifestations may include , night blindness, or delayed . Biochemical confirmation typically uses fasting serum or plasma zinc concentration, with levels below 70 μg/dL (10.7 μmol/L) in adults suggesting deficiency, though normal ranges span 66-110 μg/dL depending on laboratory standards and adjusted for age (e.g., <60 μg/dL in children under 10 years). However, plasma zinc reflects only ~0.1% of total body zinc and is tightly homeostatically regulated, decreasing acutely during inflammation, infection, or stress due to redistribution to tissues and hepatic sequestration via cytokines like interleukin-6, thus potentially underestimating chronic deficiency. Marginal cases (<80 μg/dL) may require supportive evidence from low serum alkaline phosphatase (a zinc metalloenzyme) or erythrocyte metallothionein levels, while urinary zinc excretion <0.5 mg/day post-chelation challenge can indicate depleted stores. Therapeutic trial of oral zinc (e.g., 15-30 mg elemental zinc daily) with clinical response supports diagnosis, particularly in at-risk populations. Population-level risk assessment by organizations like the International Zinc Nutrition Consultative Group uses adjusted cutoffs (e.g., <65 μg/dL prevalence >20% indicates concern), prioritizing non-fasting samples to avoid diurnal variability.

Severity classifications

Zinc deficiency is classified into mild, moderate, and severe categories primarily based on serum or plasma concentrations, though thresholds vary across studies and populations due to factors like , age, and time of day. Normal serum levels in adults typically range from 70 to 120 μg/dL, with deficiency generally indicated below 70 μg/dL; however, acute-phase responses can elevate or suppress these values, limiting reliability for mild cases. In clinical contexts, particularly among critically ill patients, severe deficiency is defined as serum zinc ≤50 μg/dL, moderate as 51–60 μg/dL, and mild as 61–70 μg/dL, with levels ≥71 μg/dL considered normal. Other frameworks categorize deficiency as <60 μg/dL (with marginal deficiency at 60–80 μg/dL) or severe below 40 μg/dL, reflecting associations with pronounced clinical outcomes like increased mortality risk in severe cases. Severe deficiency, often linked to genetic disorders such as or extreme , manifests with overt symptoms including profound growth stunting, refractory , alopecia, and acral . Moderate deficiency involves subtler impairments, such as delayed , reduced taste acuity, and compromised , while mild or subclinical forms may lack evident signs but contribute to increased susceptibility and subtle growth delays, especially in children. Classifications also distinguish acute deficiency, arising rapidly from events like prolonged zinc-free , from chronic forms driven by sustained dietary inadequacy or , with the latter more prevalent in developing regions. Diagnosis beyond serum levels often incorporates functional indicators like low activity or erythrocyte , as static biomarkers alone underestimate tissue-level deficits in non-severe cases.

Epidemiology

Global and regional prevalence

Zinc deficiency prevalence is typically assessed through population-level estimates of inadequate dietary zinc intake, where the proportion exceeding physiological requirements indicates risk, or via biomarkers such as plasma zinc concentrations, though the latter underestimates mild cases due to homeostatic regulation. Globally, approximately 17.3% of the population is estimated to be at risk of inadequate zinc intake, equating to over 1 billion individuals, based on modeling national food supply data against age- and sex-specific requirements. For children under 5 years, a 2020 meta-analysis reported a prevalence of 22%, affecting about 149 million children, with higher rates linked to diets low in bioavailable zinc sources like animal products. These figures align with broader micronutrient deficiency burdens, where over 2 billion people worldwide face risks from deficiencies including zinc, predominantly in low- and middle-income countries. Regionally, prevalence varies markedly by dietary patterns, soil zinc content affecting crop bioavailability, and socioeconomic factors. In , risk of inadequate intake reaches 30% across populations, driven by reliance on plant-based diets with high phytate content that inhibits absorption, while shows 24% risk, compounded by infectious disease burdens increasing requirements. South and , alongside , exhibit 17–29.6% population-level inadequacy based on intake data. In contrast, high-income regions like and report low prevalence, often below 10%, attributable to diverse diets rich in zinc-dense foods and practices, though subclinical deficiencies may occur in vulnerable subgroups such as the elderly or those with . Data gaps persist in many areas, with estimates relying on modeling rather than comprehensive surveys, potentially underrepresenting variability within countries.

At-risk populations

Certain populations exhibit elevated risk of zinc deficiency due to dietary patterns, physiological demands, or environmental factors. Globally, an estimated 17.3% of individuals are at risk of inadequate zinc intake, with higher prevalence in regions reliant on plant-based diets high in absorption-inhibiting phytates, such as (up to 24%) and . In low- and middle-income countries, where proteins predominate, nearly 2 billion people may face deficiency, primarily from low bioavailability rather than absolute shortages. Young children, particularly those under 5 years in developing regions, represent a high-risk group, with deficiency linked to stunting, impaired immunity, and cognitive delays; prevalence can exceed 40% in low-income settings. Pregnant and lactating women face increased needs (up to 11-12 mg/day), with studies indicating low intake in 47% or more globally, exacerbating maternal and fetal risks like . In industrialized nations, elderly individuals and children are vulnerable due to reduced absorption, lower , or chronic conditions, with suboptimal status affecting 4-73% depending on the country. Vegetarians and vegans, especially those consuming high-phytate grains without sufficient animal sources, show heightened risk from poor , as plant-based is less absorbable than from or . and adopted children from endemic areas often present with mild-to-moderate deficiency upon arrival. Zinc deficiency contributes substantially to the global burden of disease, particularly in low- and middle-income countries, where it exacerbates infectious diseases, impairs growth, and increases mortality risk among vulnerable . An estimated 17.3% of the world's is at risk of inadequate intake, with higher prevalence in regions reliant on plant-based diets low in bioavailable . In 2014, the attributed approximately 800,000 annual deaths to deficiency, with roughly half occurring in children under five years old, primarily through worsened outcomes in and . More targeted estimates indicate around 116,000 child deaths yearly linked to the condition, underscoring its role in pediatric morbidity. The disability-adjusted life years (DALYs) lost due to zinc deficiency reflect its multifaceted impacts, including contributions to stunting, immune dysfunction, and non-communicable diseases like and cardiovascular conditions. Globally, zinc deficiency accounts for DALYs lost at rates such as 74.2 per 100,000 population from and , alongside smaller shares from (17.6 per 100,000) and cancer (8.8 per 100,000). In children under five, the age-standardized DALY rate attributable to zinc deficiency declined from 24.885 per 100,000 in 1990 to 3.858 per 100,000 in 2019, driven by nutritional interventions and improved dietary diversity in some regions. However, absolute burdens remain elevated in and , where prevalence exceeds 25% in many populations, signaling persistent elevated risk. Temporal trends show a mixed picture: while age-standardized metrics have improved, overall has stabilized at high levels, affecting over 2 billion people worldwide as of recent assessments. Global Burden of Disease studies report reduced attributable burdens for deficiency in 2019 compared to prior iterations, reflecting methodological refinements and intervention effects like fortification and supplementation programs. Despite these gains, inadequate intake risks persist in 60% of low- and middle-income countries with stunting rates above 20%, often intertwined with zinc shortfalls, limiting further progress without addressing root causes like soil depletion and dietary patterns.

Causes and Risk Factors

Inadequate dietary intake

Inadequate dietary intake of primarily arises from diets low in bioavailable sources, such as animal proteins including , , , and , which provide the majority of absorbable in typical diets. The recommended dietary allowance (RDA) for is 11 mg per day for adult men and 8 mg per day for non-pregnant adult women, with higher requirements during (11 mg) and (12 mg). Diets predominantly composed of plant-based foods like cereals, , and grains often result in insufficient intake due to both lower content and the presence of inhibitors such as phytates that reduce , leading to an estimated 17.3% of the global population being at risk of inadequate consumption. Vegetarians and vegans face elevated risks of low zinc intake, as plant-derived zinc is less efficiently absorbed, necessitating 50% higher intakes to meet requirements compared to omnivorous diets. Elderly individuals are particularly susceptible due to reduced caloric intake, diminished appetite, and potential chewing difficulties, which limit consumption of zinc-rich foods. Food insecurity exacerbates this issue, especially in low-income regions where reliance on zinc-poor staples predominates, contributing to chronic deficiency as the leading cause of suboptimal zinc status worldwide. In such contexts, quantitative dietary surveys consistently identify insufficient protein and zinc co-content in foods as a key driver. Global estimates indicate higher prevalence in (19%) and (24%), where dietary patterns favor unrefined grains and limited animal products, underscoring the role of socioeconomic factors in perpetuating inadequate intake. Interventions focusing on dietary diversification or have shown potential to mitigate risks, though persistent challenges in access to nutrient-dense foods maintain the burden.

Malabsorption and gastrointestinal factors

Zinc absorption occurs primarily in the proximal , where and transporters like ZIP4 facilitate uptake, but syndromes disrupt this process by damaging enterocytes or reducing absorptive surface area. Conditions such as celiac disease cause villous atrophy in the and , leading to impaired zinc uptake and documented deficiencies in affected patients. Similarly, inflammatory bowel diseases like result in poor intestinal absorption due to chronic inflammation and mucosal damage, even when the jejunum remains relatively spared. Short bowel syndrome, often following surgical resection, drastically reduces the absorptive length of the , exacerbating zinc losses and necessitating higher supplemental doses exceeding 50 mg elemental daily in severe cases. Chronic diarrhea from various gastrointestinal etiologies further promotes deficiency by accelerating transit time and binding to unabsorbed fatty acids or other luminal factors, impairing . Bariatric procedures, such as gastric bypass, contribute by bypassing key absorptive sites and inducing rapid weight loss with associated . Prevalence of zinc deficiency in these populations is significant, affecting 15% to 40% of individuals with inflammatory bowel diseases, underscoring the causal link between gastrointestinal pathology and depletion. Supplementation strategies must account for these factors, as standard dietary intake often fails to compensate for heightened requirements in malabsorptive states.

Increased excretion and losses

Zinc losses through increased gastrointestinal excretion represent a primary mechanism of depletion, particularly in conditions involving or secretory . Persistent elevates fecal zinc output, with patients experiencing losses of up to 6-12 mg per day, necessitating supplemental in clinical settings such as total . In such cases, recommendations include adding 12 mg of per liter of gastrointestinal fluid lost from sources like fistulas, stomas, or ostomies to counteract depletion. These losses arise from disrupted intestinal and accelerated transit, reducing net absorption and amplifying endogenous secretions into the gut lumen. Urinary excretion of can rise under physiological stress or pharmacological influence, contributing to systemic deficiency. Chronic induces hyperzincuria through impaired renal and hepatic dysfunction, lowering tissue stores. Similarly, prolonged therapy, such as thiazides or loop agents, enhances urinary elimination, with studies documenting measurable declines in serum levels among users. Conditions like chronic renal further exacerbate this by altering glomerular filtration and tubular handling of zinc-binding proteins. Dermal and exudative losses occur via sweat and effluvia, particularly in high-stress scenarios. Normal sweat zinc output averages 0.2-0.6 mg daily, but intensifies to several milligrams per day during profuse from exercise or heat exposure, potentially tipping marginal intakes into deficiency. Severe burns provoke substantial transudative losses from damaged , with requirements escalating to offset exudates rich in -containing plasma proteins, as evidenced by reduced rates with aggressive supplementation. These pathways underscore 's vulnerability in catabolic states where homeostatic adjustments in absorption fail to compensate for accelerated output.

Comorbid conditions and medications

Certain chronic gastrointestinal disorders, such as , celiac disease, and short-bowel syndrome, predispose individuals to zinc deficiency primarily through impaired intestinal absorption and increased enteric losses. Similarly, syndromes and conditions involving enterocutaneous fistulae exacerbate zinc , leading to conditioned deficiency states. contributes via reduced hepatic storage and altered plasma transport proteins, while is associated with hyperzincuria and inflammation-driven losses. In , zinc deficiency arises from dysregulated homeostasis, including reduced renal reabsorption and dialysis-related depletion in patients. Other comorbidities linked to zinc deficiency include infection, where immune activation and diarrhea promote losses, and , potentially through impairing zinc uptake in tissues. may compound this via dysregulation affecting zinc metabolism, though evidence remains associative rather than strictly causal. Psychiatric conditions like depression show correlations with low serum zinc, possibly bidirectional with deficiency exacerbating symptoms, but confounding factors such as diet and require cautious interpretation. Medications can precipitate or worsen zinc deficiency by interfering with absorption, enhancing urinary excretion, or competing for transport pathways. Diuretics, including and , increase renal zinc losses, particularly in patients. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) induce zincuria, as observed in clinical studies of management. , used in , chelates zinc and causes severe deficiency, necessitating supplementation. Antibiotics, systemic antibacterials, and anticonvulsants like sodium may impair gut absorption or alter microbial zinc handling. Corticosteroids and have been associated in observational data, potentially via catabolic effects or metabolic shifts. Monitoring serum zinc is recommended in patients on these therapies, especially with comorbid risks.

Pathophysiology

Biochemical and molecular mechanisms

serves as a catalytic cofactor for over 300 enzymes involved in diverse biochemical processes, including DNA and activity, protein synthesis, and function, while also providing structural integrity to motifs in transcription factors essential for . Intracellular is maintained through a dynamic interplay of influx transporters from the ZIP (SLC39A) family, which facilitate Zn²⁺ entry into the from extracellular spaces or intracellular vesicles; efflux transporters from the ZnT (SLC30A) family, which export or sequester it into organelles; and metallothioneins (MTs), cysteine-rich proteins that buffer approximately 5-15% of cellular by binding up to seven Zn²⁺ ions per molecule. The metal-responsive transcription factor 1 (MTF-1) acts as a primary , translocating to the nucleus upon detecting low cytosolic levels (in the nanomolar to sub-micromolar range) to bind metal response elements (MREs) and induce expression of MT genes, certain ZIP and ZnT transporters, and other zinc-responsive targets. In zinc deficiency, compensatory mechanisms such as upregulation of intestinal ZIP4 expression fail to fully restore systemic availability, resulting in depleted cytosolic and organelle-specific zinc pools that disrupt and protein stability. For instance, reduced zinc availability impairs the activity of zinc-dependent enzymes like and , compromising metabolic pathways and defenses. Metallothioneins undergo degradation to release bound zinc, but chronic deficiency overwhelms this , leading to dysregulated MTF-1 signaling and altered expression of genes. Molecularly, zinc deficiency elevates (ROS) production and by diminishing MT-mediated radical scavenging and Nrf2 pathway activation, which normally upregulates enzymes such as heme oxygenase-1 (HO-1). This oxidative imbalance activates pro-inflammatory transcription factors like , enhancing production (e.g., TNF-α, IL-6) through increased binding and reduced inhibitory controls like A20. Additionally, low inhibits signaling cascades, including ERK and AKT pathways, promoting cell cycle arrest at G1/ via stabilization and limiting proliferation, while in some contexts triggering caspase-3-mediated through intracellular and DNA fragmentation. These disruptions extend to zinc-trafficking proteins like ZIP13 in the , impairing and secretory pathway function.

Systemic impacts

Zinc deficiency disrupts systemic cellular by impairing zinc-dependent enzymes and transcription factors, leading to widespread dysregulation of and protein function across multiple organs. As a cofactor in over 300 enzymes involved in , RNA transcription, and , its depletion causes reduced and increased , manifesting as histopathological changes in tissues including the skin, gastrointestinal tract, eyes, reproductive organs, and . A primary systemic consequence is heightened due to diminished activity of antioxidant enzymes like copper-zinc (Cu/Zn-SOD), which fails to adequately scavenge radicals, resulting in , protein oxidation, and DNA damage throughout the body. This oxidative imbalance, compounded by downregulation of metallothioneins—zinc-binding proteins that buffer —amplifies cellular injury and promotes chronic low-grade , particularly in models of where zinc-deficient states correlate with elevated levels and multi-organ dysfunction. Immune system impairment represents another broad systemic effect, with zinc deficiency inducing , suppressed T-lymphocyte maturation, and skewed profiles that favor pro-inflammatory Th2 responses over protective Th1 immunity. This leads to compromised host defenses against pathogens, facilitating systemic infections that exacerbate tissue damage via unchecked microbial translocation across compromised epithelial barriers, as seen in gastrointestinal epithelia where integrity is lost. In vulnerable populations, such as those with chronic illnesses, this immune dysregulation heightens susceptibility to secondary complications like and through disrupted hematopoiesis. Developmentally, zinc deficiency hinders systemic growth processes by interfering with signaling and protein synthesis, resulting in stunted organ development and metabolic inefficiencies that persist into adulthood. Neurologically, it promotes neuronal vulnerability via elevated and reduced neuroprotective signaling, contributing to cognitive deficits and heightened risk of neurodegenerative pathways through unchecked oxidative damage in the . These interconnected effects underscore zinc's role as a critical modulator of systemic resilience, where deficiency acts as a multiplier of stress responses, increasing overall morbidity in affected individuals.

Clinical Manifestations

Dermatological and integumentary effects

Zinc deficiency manifests dermatologically through impaired epithelial integrity and proliferation, leading to characteristic periorificial and acral . This presents as erythematous, scaly, vesiculobullous, or pustular eruptions that evolve into erosions, oozing, and secondary crusting, primarily affecting areas around the mouth, eyes, nose, anus, and distal extremities such as hands and feet. In severe cases, these lesions mimic , a genetic zinc disorder, but occur in acquired deficiency due to dietary insufficiency or . and are common adjunct features, with infections exacerbating the erosive process owing to compromised barrier function. Alopecia, ranging from patchy to diffuse, arises from disrupted hair follicle morphogenesis and anagen phase arrest, as zinc is essential for metalloenzymes involved in synthesis and cellular division. Nail dystrophy accompanies these changes, manifesting as brittle nails, (longitudinal ridging), (transverse grooves indicating growth arrest), and (white discoloration). These integumentary alterations reflect zinc's role in DNA transcription and antioxidant defense, where deficiency promotes and delayed epithelial repair. Wound healing is profoundly impaired, with reduced deposition and activity, prolonging recovery from even minor trauma and increasing risk. Pigmentary disturbances, including hyper- or , may occur secondary to dysfunction, though less consistently documented. Supplementation typically reverses these effects within weeks, underscoring the causal link, though chronic deficiency risks scarring or persistent if untreated.

Oral and mucosal symptoms

Zinc deficiency manifests in the oral cavity primarily through inflammatory changes affecting the lips, tongue, and buccal mucosa, including angular cheilitis, glossitis, and stomatitis. Angular cheilitis presents as erythematous, fissured, or crusted lesions at the labial commissures, often linked to nutritional deficiencies such as zinc alongside iron or B vitamins, with zinc's role in epithelial integrity and immune function implicated in pathogenesis. Glossitis appears as tongue inflammation, potentially smooth, atrophic, or fissured, contributing to symptoms like dysgeusia or pain, as observed in cases of acquired zinc deficiency post-gastrointestinal surgery. Stomatitis in zinc-deficient states involves mucosal , ulceration, or , with lower serum levels correlated in patients with recurrent compared to controls, suggesting a contributory role in mucosal barrier impairment. Clinical trials demonstrate that zinc supplementation shortens healing time, reduces pain and lesion diameter, and decreases recurrence of recurrent aphthous stomatitis, particularly in zinc-deficient patients; local zinc formulations, such as mucoadhesive tablets, provide direct symptom relief, though some double-blind studies show mixed results in non-deficient individuals with overall greater benefits in deficient cases. In severe deficiencies, such as —a of absorption— extends to mucosal involvement with erosions, pustules, and secondary infections, resolving rapidly upon supplementation at doses of 1-3 mg/kg elemental daily. These symptoms arise from zinc's essential functions in proliferation, , and defense within mucosal tissues, where deficiency disrupts tight junctions and promotes ; clinical improvement following zinc repletion, as in cases, further supports causality over mere association. Acquired deficiencies, often from or increased losses, mimic these presentations, with mucosal healing observed within days of therapy in documented cases.

Sensory impairments

Zinc deficiency impairs gustatory function, leading to (reduced taste sensitivity) and (distorted taste perception). These effects arise from zinc's role in the synthesis and secretion of gustin, a isoenzyme essential for maturation and function; low salivary zinc levels correlate with diminished gustin activity and taste acuity loss. Clinical studies demonstrate that patients with idiopathic often exhibit deficiency, with oral zinc supplementation (typically 50-100 mg elemental daily) restoring taste function in responders, as evidenced by improved acuity thresholds within weeks. Olfactory impairment, including and , frequently accompanies zinc deficiency, particularly in cases involving mucosal or neurological disruption. Zinc supports function and epithelial integrity; deficiency disrupts these processes, mimicking patterns seen in acute zinc depletion syndromes. Observational data link low serum zinc to persistent smell loss, with normalization via supplementation aiding recovery in deficient individuals, though efficacy varies with underlying . Visual disturbances manifest as (night blindness) due to zinc's necessity in vitamin A metabolism, including transport and regeneration in rod cells. Severe deficiency impairs dark adaptation by hindering activity, exacerbating mobilization deficits; case reports document reversible following zinc repletion in malnourished or cirrhotic patients. has also been reported in profound cases, resolving with treatment. Auditory deficits, such as and , emerge from zinc's involvement in cochlear ribbon synapse maintenance and antioxidant defense against . Experimental models show zinc depletion reduces synaptic ribbons in inner cells, correlating with elevated auditory thresholds; human studies associate hypozincemia with progressive hearing impairment, particularly in noise-exposed or elderly populations, where supplementation mitigates severity in deficient cases.

Immune dysfunction

Zinc deficiency impairs , resulting in thymic atrophy, reduced T-lymphocyte proliferation, and diminished production essential for immune defense. In experimental human models, zinc deprivation induces lymphopenia, decreased activity, and impaired , collectively contributing to severe immune dysfunction. These effects stem from zinc's role as a cofactor for over 300 enzymes, including those involved in and within immune cells, where deficiency disrupts thymic epithelial cell function and T-cell maturation. At the molecular level, zinc deficiency promotes a pro-inflammatory state by dysregulating signaling, leading to excessive production of (ROS) and impaired hematopoiesis, which hampers both innate and adaptive responses. Adaptive immunity suffers particularly from reduced Th1 cytokine secretion, including interleukin-2 (IL-2), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ), while B-cell production declines due to faulty maturation. Innate components, such as and , are similarly compromised, exacerbating vulnerability to pathogens. Clinically, zinc-deficient individuals exhibit heightened infection risk, including infections and , with studies linking low serum zinc to increased incidence and severity of conditions like caused by . In vulnerable populations, such as the elderly or those with chronic conditions, deficiency correlates with prolonged recovery from infections and higher mortality rates, as observed in cohorts with suboptimal levels during respiratory illnesses. Supplementation trials demonstrate partial reversal of these deficits, underscoring 's causal role in maintaining immune homeostasis.

Gastrointestinal symptoms

Zinc deficiency commonly manifests in the as persistent , particularly in infants and young children, where it serves both as a symptom and a perpetuating factor through increased fecal zinc losses. This bidirectional relationship is evident in clinical observations where severe deficiency, such as in , presents with profuse, watery alongside , exacerbating nutritional deficits. Empirical data from supplementation trials in zinc-deficient populations, including children in developing regions, demonstrate that correcting deficiency reduces duration by approximately 20-25%, underscoring the causal role of low status in impairing mucosal integrity and handling. Anorexia and reduced appetite are additional GI symptoms linked to zinc deficiency, arising from altered taste perception () and direct effects on gut and satiety signaling. Zinc's role in maintaining function and integrity explains these effects; deficiency induces intestinal hyperpermeability, or "leaky gut," which promotes and further impairs nutrient absorption, including water and electrolytes, thereby prolonging diarrheal episodes. In animal models and human studies of marginal deficiency, this hyperpermeability correlates with and elevated , disrupting barrier function without overt infection. Other manifestations include subtle absorptive defects, such as delayed gastric emptying or hypochlorhydria in chronic cases, though these are less consistently documented than . Clinical reviews emphasize that while predominates in pediatric deficiency, adults with acquired hypozincemia from malabsorptive conditions may experience nonspecific symptoms like or secondary to mucosal . Diagnosis often requires correlating these symptoms with low plasma zinc levels (<70 μg/dL), as isolated GI complaints overlap with other etiologies.

Neurological and cognitive effects

Zinc plays a critical role in function, including synaptic transmission, , and defense, with deficiency disrupting these processes and leading to neuronal and impaired hippocampal activity. In animal models, zinc deficiency induces cognitive decline, including deficits in learning and memory, alongside increased and neurodegeneration. Human studies corroborate these findings, showing subclinical zinc deficiency impairs neuropsychological performance, such as and executive function, in randomized controlled trials among children and adults. Cognitive effects manifest as reduced , slower processing speed, and impairment, particularly in vulnerable populations like the elderly or those with marginal intake. A 2025 identified zinc deficiency as an independent risk factor for new-onset , with a dose-response relationship where lower serum levels correlated with higher incidence rates over follow-up periods. In children from low-income settings, zinc-deficient groups exhibited poorer performance on tests of visuospatial ability and psychomotor speed, with supplementation yielding modest improvements in some trials but null effects in others, suggesting context-dependent causality influenced by baseline status. Neurological symptoms include , , and mood disturbances, linked to altered neurotransmitter modulation, such as reduced GABA and function. Zinc deficiency exacerbates neurodegenerative progression, as evidenced in Alzheimer's models where low zinc potentiates activation and amyloid-beta accumulation, accelerating cognitive decline. Associations with depression are consistent, with serum zinc levels markedly lower in patients compared to controls, and deficiency contributing to hippocampal volume reduction via impaired . However, meta-analyses indicate inconsistent supplementation benefits for broad cognitive outcomes in non-deficient populations, underscoring that effects are most pronounced in confirmed deficiency states rather than universal prophylaxis. Overall, these impairments arise from zinc's essentiality in over 300 enzymes and its modulation of signaling, with deficiency thresholds below 70 μg/dL plasma zinc reliably predicting functional deficits in longitudinal data.

Growth and developmental delays

Zinc deficiency is a well-established cause of linear growth retardation and stunting in children, particularly in regions with high rates of , where it contributes to 10-15% of growth faltering cases according to systematic reviews. This manifests as reduced height-for-age z-scores, with affected children often failing to achieve expected percentiles even after catch-up growth opportunities. is similarly impaired, leading to low weight-for-height in severe cases. In prepubertal children with confirmed deficiency, supplementation has demonstrated statistically significant increases in both linear growth and body weight, underscoring zinc's causal role in somatic development. At the molecular level, zinc facilitates DNA and RNA polymerase activity, cell division, and protein synthesis, all critical for tissue proliferation during growth phases. Deficiency disrupts the growth hormone-insulin-like growth factor 1 (GH-IGF-1) axis, reducing basal IGF-1 and IGF-binding protein-3 levels while impairing GH signaling and receptor binding, though these hormonal changes do not fully account for the growth inhibition observed. Zinc also modulates alkaline phosphatase and osteocalcin, markers of bone formation, further linking it to longitudinal bone growth. In zinc-depleted models, hepatic IGF-1 gene expression declines, and supplementation restores these pathways, promoting mitogenic responses. Preventive zinc supplementation trials, especially in children under 5 years from low- and middle-income countries, show modest but consistent benefits on linear growth, with meta-analyses reporting net height gains of approximately 0.37 cm (95% CI: 0.12-0.62 cm) from 10 mg daily doses over 24 weeks in stunted individuals. Effects are more pronounced when is given alone rather than co-supplemented with iron, potentially due to absorption interference, and in populations with baseline deficiency or recent illness episodes. In preterm infants, routine enteral (e.g., 3-4 mg/kg/day) independently associates with improved length , reducing the incidence of extrauterine growth restriction without elevating serum excess. However, benefits wane post-24 months if underlying persists, highlighting the need for sustained intervention. Developmental delays beyond physical growth, including motor and cognitive impairments, show weaker and more variable evidence. Animal and human studies suggest zinc deficiency delays motor milestones and cognitive processes like and , possibly via impaired neuronal proliferation and synaptic function during critical windows. Low hair zinc levels correlate with cognitive and language delays in infants aged 9-24 months, with odds ratios indicating heightened in deficient cohorts. Yet, randomized trials often find no significant impact on standardized developmental scores at 6-12 months, even with supplementation, implying that associations may reflect factors like overall rather than zinc-specific causality. In small-for-gestational-age infants, early zinc status predicts motor outcomes, but supplementation effects remain inconsistent across meta-analyses.

Reproductive and hormonal effects

Zinc deficiency impairs male reproductive function primarily through disruptions in testosterone synthesis, , and testicular atrophy. Serum testosterone concentrations decrease in zinc-deficient states, contributing to reduced libido and potential erectile dysfunction, as zinc serves as a cofactor for enzymes involved in steroidogenesis, such as 17β-hydroxysteroid dehydrogenase. Experimental dietary zinc restriction in humans has demonstrated reduced sperm counts, with reversible upon repletion, indicating a direct causal link; studies also show impaired testicular growth and function, including atrophy in deficiency models, and supplementation with 15-30 mg elemental zinc daily in deficient individuals supports testosterone synthesis, libido, and sperm quality, with pairing to copper recommended to avoid absorption interference. In seminal plasma, zinc levels are significantly lower among infertile males compared to fertile controls, correlating with diminished , viability, and overall quality due to impaired and . Zinc deficiency also promotes testicular via elevated cytokines, further compromising gonadal tissue and receptor activity. In females, zinc deficiency disrupts development and maturation, resulting in fewer total and mature follicles observable in histological studies of deficient models. It is associated with increased risk of , with maternal serum levels significantly lower in women experiencing loss compared to those with successful outcomes. During , deficiency heightens susceptibility to fetal growth retardation, congenital malformations, and neural developmental impairments through mechanisms including and altered in reproductive tissues. 's role extends to regulating growth and implantation, where inadequacy leads to dysfunctional progesterone and signaling. Hormonally, zinc deficiency correlates inversely with circulating testosterone across systematic reviews, potentially via reduced receptor sensitivity and function in males. In both sexes, it exacerbates severity, particularly emotional symptoms, as evidenced by meta-analyses showing symptom alleviation with supplementation, implying baseline deficiency disrupts and sex steroid balance. These effects underscore zinc's integral function in maintaining hypothalamic-pituitary-gonadal axis integrity, with deficiency precipitating hypogonadism-like states reversible by targeted repletion in clinical observations.

Diagnosis

Laboratory assessments

Serum or plasma concentration is the most commonly used laboratory for assessing status, with levels below 70 μg/dL typically indicating deficiency in adults, though cutoffs vary by guideline and population. Normal ranges are generally 66–106 μg/dL in adults without acute illness, but concentrations can fluctuate diurnally and decrease as an acute-phase response during , , or stress, potentially masking true deficiency. Thus, serum is better suited for confirming overt deficiency in symptomatic patients rather than routine screening or assessing tissue stores, as it reflects only circulating , which comprises less than 0.1% of total body . Adjustments for inflammatory markers, such as or alpha-1-acid glycoprotein, are recommended to interpret serum zinc accurately in populations with high infection rates, using regression models to estimate the inflammation-adjusted concentration. In children and pregnant individuals, lower thresholds (e.g., <60 μg/dL for deficiency) may apply due to physiological demands, but evidence for population-specific norms remains limited. For monitoring, urinary zinc excretion provides a complementary measure, as it correlates with recent intake. Alternative biomarkers include erythrocyte , which reflects longer-term status (3–4 months) but requires specialized processing to avoid artifacts; hair , useful for chronic deficiency assessment in healthy individuals yet unreliable in those with metabolic disorders; and urinary , which indicates recent losses but varies with hydration. -dependent enzymes like or in plasma can signal functional deficits, though they lack specificity. No single fully captures status due to its ubiquitous metabolic roles, prompting panels to advocate combining laboratory measures with dietary intake data and clinical signs for . Emerging explores exchangeable pool size via stable tracers as a more sensitive indicator of mobilizable , though it is not yet clinically routine.

Clinical evaluation and differential diagnosis

Clinical evaluation of zinc deficiency relies on a detailed history and physical examination to identify suggestive features and risk factors, as symptoms are often nonspecific and overlap with other conditions. History should probe dietary habits, such as vegetarian or high-phytate intake, malabsorptive states like or post-bariatric surgery, increased losses from chronic diarrhea or burns, excessive alcohol use, pregnancy, or chronic illnesses including liver and . In children, inquire about or delayed milestones; in adults, note symptoms like , anorexia, or disturbances. Physical findings characteristically include periorificial and acral dermatitis resembling eczematous or psoriasiform plaques around the mouth, eyes, anus, and extremities, often with vesiculobullous lesions or pathergy. Alopecia, nail dystrophy such as Beau's lines or paronychia, angular cheilitis, glossitis, and stomatitis are common integumentary signs. Systemic examination may reveal growth retardation or hypogonadism in children and adolescents, impaired wound healing, night blindness, or neurological features like irritability and hypogeusia. In severe inherited forms like acrodermatitis enteropathica, symptoms emerge post-weaning with irritability, recurrent infections, and diarrhea. A presumptive diagnosis can be supported by rapid improvement in symptoms following zinc supplementation, typically 1-3 mg/kg/day orally. Differential diagnosis encompasses other nutritional deficiencies and dermatological or systemic disorders with similar manifestations, necessitating exclusion through clinical context and targeted testing. , , or deficiencies present with comparable periorificial but differ in response to specific repletion. or may mimic skin lesions but lack acral distribution and associated systemic features like alopecia or infections. from features annular erythema with elevated glucagon levels, while involves photosensitive distinguishable by niacin deficiency history. Protein-energy or multiple deficits, such as iron or deficiencies, overlap in growth impairment and but require broader nutritional assessment. Genetic , though zinc-related, is differentiated by autosomal recessive inheritance and early onset, confirmed via SLC39A4 mutation analysis. Conditions like , , or must be ruled out based on absence of zinc-responsive features. Therapeutic trial with , alongside exclusion of mimics, aids definitive attribution.

Treatment

Supplementation protocols

Supplementation protocols for deficiency emphasize of elemental to replete stores, with dosages tailored to age, severity, and . Common forms include , gluconate, acetate, or oxide, where the elemental content varies (e.g., 23% in , 14% in gluconate); labels specify elemental amounts for accurate dosing. typically begins with higher therapeutic doses to correct deficiency, followed by maintenance at or near recommended dietary allowances (RDAs) once serum levels normalize, with regular monitoring via plasma or serum concentrations to avoid over-supplementation. For severe genetic deficiencies like , lifelong supplementation at 1–3 mg/kg/day of elemental is standard, often divided into multiple doses to enhance absorption and minimize gastrointestinal upset. In acquired deficiencies, such as those from or chronic disease, initial doses of 0.5–1 mg/kg/day (or 20–50 mg/day for adults) for 3–6 months are employed until clinical resolution and normalized status, adjusted based on response.
PopulationTherapeutic Dosage (Elemental )DurationNotes
Infants/Children (<6 months)10 mg/day10–14 days (e.g., for diarrhea-associated deficiency)WHO/UNICEF guideline; extend if chronic deficiency confirmed.
Children (6 months–5 years)20 mg/day10–14 days to monthsFor acute treatment; higher (1–3 mg/kg/day) in severe cases.
Adults20–50 mg/dayWeeks to months2–3 times RDA for mild cases; medical supervision for higher doses.
Pregnant/Lactating Women11–15 mg/day (maintenance post-repletion)Ongoing as neededIncreased RDA; therapeutic doses under guidance to prevent fetal risks from excess.
Protocols recommend taking zinc on an empty stomach in the fasted or morning state for optimal absorption, though with if occurs, while avoiding concurrent intake with iron, calcium, or phytate-rich foods that inhibit uptake. Intravenous may be used in syndromes or critical illness, at 3 mg/kg/day initially, but oral routes suffice for most cases. Efficacy requires addressing underlying causes, such as dietary inadequacy or gastrointestinal disorders, alongside supplementation.

Evidence of efficacy

Zinc supplementation effectively raises serum zinc concentrations in individuals with confirmed deficiency, as demonstrated by randomized controlled trials measuring plasma levels before and after intervention. In a of clinical trials, supplementation at doses of 10-20 mg elemental daily normalized zinc status in deficient children and adults within 4-6 weeks, with enhanced by forms like or gluconate. In pediatric populations with zinc deficiency, supplementation reduces the duration of acute by approximately 20-25%, particularly in those under 5 years old in low-income settings, according to multiple meta-analyses of randomized trials involving over 6,000 participants. A Cochrane review of 25 trials confirmed this effect, attributing it to zinc's role in immune modulation and epithelial repair, with greater benefits observed in baseline-deficient subgroups. Incidence of subsequent episodes also decreases by 13-15%. For growth outcomes, long-term zinc supplementation (6-18 months) in deficient children improves linear growth velocity by 0.2-0.5 cm per month and , as evidenced by meta-analyses of trials in and , where stunting prevalence correlates with low intake. The effect is most pronounced in children aged 6 months to 12 years, supporting zinc's causal role in and cellular proliferation. However, benefits diminish in zinc-replete populations. Zinc therapy decreases infection-related morbidity, including and overall infectious episodes, by enhancing T-cell function and reducing markers like CRP and MDA, per meta-analyses of supplementation in deficient cohorts. In HIV-positive adults with low , 12-18 mg daily delayed immunological decline and reduced incidence over 18 months in a randomized . is limited in non-deficient individuals, where supplementation shows no mortality benefit or may increase risks like .

Potential risks and adverse effects

Short-term oral zinc supplementation, particularly at doses exceeding 40 mg elemental per day, commonly induces gastrointestinal disturbances including , , , abdominal cramps, and a metallic in the . These effects typically onset within 3 to 10 hours of and resolve upon discontinuation, but they occur in up to 20-30% of users depending on formulation and dose. In pediatric populations receiving therapeutic doses of 10-20 mg daily for deficiency, studies report elevated incidence in approximately 30% of cases compared to . Chronic supplementation at high doses (e.g., 50-150 mg daily) risks inducing through of intestinal absorption, manifesting as , , , and neurological sequelae such as , , or gait instability. This iatrogenic hypocupremia has been documented in case series involving prolonged use for conditions like or self-treatment, with serum copper levels dropping below 70 mcg/dL after months of excess intake; reversal requires cessation and repletion. may also impair iron absorption, exacerbating in vulnerable groups, and lower HDL cholesterol levels by 10-20% in long-term users. Acute from overdoses (e.g., 10-30 grams) can precipitate severe , , , and , with potential fatalities reported in ingestions above 4-8 grams. and reduced neutrophil function have been observed with intakes over 100 mg daily for weeks, increasing susceptibility. Therapeutic regimens for zinc deficiency should thus limit duration to 1-3 months, incorporate monitoring (e.g., serum levels every 3 months), and avoid in patients with hemochromatosis or renal impairment where accumulation heightens risk.

Prevention Strategies

Dietary and nutritional interventions

Dietary interventions for preventing deficiency emphasize increasing consumption of foods rich in bioavailable , particularly from animal sources, which provide higher absorption rates compared to plant-based options due to lower levels of inhibitory compounds like phytates. Recommended daily allowances (RDA) for are 11 mg for adult men and 8 mg for adult women, with higher requirements of 11-12 mg during and 12-13 mg during to support fetal development and production. Animal-derived foods such as oysters, , , , and products are primary sources of highly absorbable ; for instance, oysters contain up to 74 mg per 100 g serving, far exceeding the RDA in a single portion. Plant sources including , nuts, , whole grains, and fortified cereals contribute but exhibit reduced bioavailability, often 20-40% lower than animal sources because phytates in these foods bind and inhibit intestinal absorption. To mitigate this in plant-heavy diets common in developing regions or vegetarian patterns, strategies include soaking, , , or milling to degrade phytates, thereby enhancing uptake by up to 50% in some cases. Animal proteins in meals further promote absorption by forming complexes that facilitate uptake, while excessive intake of phytate-rich staples like and without processing can exacerbate deficiency risk, especially in populations with high dependence. For at-risk groups such as children, pregnant women, and those on -based diets, prioritizing -dense foods alongside absorption enhancers like moderate protein intake supports prevention without routine supplementation. Evidence from intervention studies indicates that shifting toward diets with greater inclusion or processed foods reduces of biochemical deficiency markers, such as low serum levels below 70 μg/dL.

Food fortification and biofortification

Food fortification involves the addition of zinc compounds, such as zinc sulfate or zinc oxide, to staple foods to enhance their micronutrient content and address population-level deficiencies. Common vehicles include wheat flour, maize flour, rice, and condiments, with recommended fortification levels of 20–50 mg/kg in flours depending on expected consumption. A meta-analysis of large-scale fortification programs indicated that zinc fortification reduced the prevalence of zinc deficiency by 24–55% in targeted populations. However, a Cochrane review of randomized trials found that while zinc-fortified staples marginally increased serum zinc concentrations, they did not significantly reduce stunting risk in preschool children (relative risk 0.88, 95% CI 0.73–1.07). Cost-effectiveness analyses suggest fortification is economical, with benefits outweighing costs in low- and middle-income countries where dietary zinc inadequacy affects public health. Biofortification, by contrast, increases zinc content inherently in crops through conventional breeding or agronomic practices, rather than post-harvest addition. Programs like HarvestPlus have developed high-zinc varieties of , , , and other staples, achieving zinc concentrations up to 30–40% higher than conventional counterparts without compromising yield. Agronomic , involving soil or foliar application of zinc fertilizers, has been shown in meta-analyses to elevate grain zinc levels by 20–50% in cereals, improving for human consumption. Efficacy studies in regions like and demonstrate that consuming biofortified crops reduces dietary zinc inadequacy, with potential reductions in deficiency prevalence by 10–20% when scaled. These approaches complement by targeting rural farming communities with limited access to processed foods, though long-term impacts on health outcomes like growth and immunity require further longitudinal data.

Public health measures

Public health measures for zinc deficiency primarily involve targeted supplementation programs, surveillance systems, and integration into existing child health initiatives, particularly in low- and middle-income countries where prevalence is high. The (WHO) and recommend zinc supplementation alongside oral rehydration solution (ORS) for children under five years with acute , reducing duration and severity by approximately 25% and preventing future episodes. This approach has been scaled nationally, as in Bangladesh's 2006 campaign, which increased zinc use for diarrhea treatment from negligible levels to over 30% coverage within years, correlating with reduced . Beyond acute treatment, preventive supplementation targets at-risk groups like pregnant women and stunted children. WHO guidelines suggest 20 mg daily for pregnant and lactating women in deficient populations, while trials show 10 mg daily for 24 weeks yielding modest height gains of 0.37 cm in under-fives. Organizations like the International Zinc Nutrition Consultative Group (IZiNCG) advocate for population-level monitoring using biomarkers such as plasma concentrations below 70 μg/dL to guide interventions. The Saves Kids initiative, launched in , promotes global awareness and program integration, emphasizing co-administration with or to enhance efficacy and coverage. Surveillance and policy frameworks ensure sustained impact; for instance, mandatory policies in countries like and have complemented supplementation by addressing dietary shortfalls, though efficacy depends on compliance and . Public education campaigns stress dietary sources like and alongside supplements to foster long-term behavioral changes, with from randomized trials indicating reduced deficiency rates when combined with improvements. Challenges include and cultural barriers, underscoring the need for intersectoral collaboration between health ministries and agriculture sectors.

Agricultural and Soil Factors

Zinc in soils and crop production

Zinc deficiency in agricultural soils is the most widespread micronutrient constraint globally, affecting over 50% of the world's arable lands and limiting crop yields as well as grain zinc concentrations. This deficiency is particularly prevalent in intensively cropped regions with high-pH, calcareous, or sandy soils, where zinc bioavailability is reduced, leading to stunted plant growth, chlorosis, and reduced seed set in cereals such as wheat, rice, and maize. In such soils, total zinc levels may be adequate, but plant-available zinc (measured as DTPA-extractable) often falls below critical thresholds, typically under 0.6–1.0 mg/kg, exacerbating hidden hunger in human diets reliant on staple crops. Soil properties dominantly control availability to crops, with being the primary factor: availability decreases sharply above 7.0 due to adsorption onto iron oxides, carbonates, and clays, forming insoluble compounds like or . High levels from fertilizers can induce deficiency by promoting zinc-phosphate precipitation in the soil solution or , while low content limits and microbial solubilization of . influences retention, with sandy soils prone to leaching losses during heavy rainfall, and clay-rich soils binding tightly, reducing uptake; additionally, flooding in paddies lowers , immobilizing through formation. biology, including root exudates and mycorrhizal associations, can enhance mobilization, but these are often insufficient in deficient soils. Zinc fertilization corrects deficiencies and boosts performance: soil-applied at rates of 5–25 kg Zn/ha increases yields by up to 1 t/ha and grain zinc by 7 mg/kg compared to unfertilized controls. Foliar sprays, effective for rapid uptake in , elevate grain zinc concentrations by 3–4 times without always proportionally increasing yield, supporting agronomic to combat deficiency. Long-term applications sustain soil pools and system productivity, as seen in rice-wheat rotations where zinc inputs improved yields by 10–20% and uptake without environmental risks like heavy metal accumulation. However, responses vary by and edaphic conditions, with soils requiring higher rates or chelated forms like Zn-EDTA for efficacy.

Biofortification efforts

efforts to combat deficiency primarily involve conventional to enhance concentrations in staple crops such as , , and , targeting regions with widespread soil limitations and human . These initiatives leverage within crop gene pools to develop varieties with 20-50% higher grain content compared to conventional types, without compromising yield or agronomic performance. Organizations like HarvestPlus, launched in 2003 under the consortium, have coordinated global breeding programs, partnering with institutions such as the International and Improvement Center (CIMMYT) to identify and introgress high- traits from wild relatives and landraces into elite breeding lines. Significant progress has occurred in , a key staple in and beyond, where high-zinc varieties can supply up to 50% of the estimated average requirement for in diets reliant on cereals. As of 2023, 19 zinc-biofortified varieties have been released in , including , and , while three varieties have been introduced in , specifically , , and . In , the Akbar-2019 variety has achieved mega-variety status, covering substantial acreage due to its yield stability and nutritional enhancement. India has released at least 16 such varieties since approximately 2015, driven by CIMMYT-led breeding that has resulted in over 20 global releases occupying millions of hectares. Similar advancements include 11 zinc varieties in Central American countries like , , and , aimed at improving dietary in maize-dependent populations. Evidence from randomized controlled trials and systematic reviews demonstrates that zinc-biofortified crops increase bioavailable absorption and improve nutritional outcomes, including modest gains in child growth and reduced incidence of deficiency-related illnesses. For instance, consumption of biofortified has been linked to enhanced linear growth in young children, while variants reduce markers of and DNA damage at physiological doses. These efforts complement agronomic practices but emphasize sustainable, seed-based delivery to reach smallholder farmers, with adoption scaling to millions of households by 2021 in target regions. Challenges persist in maintaining stability during processing and ensuring equitable distribution, though studies confirm efficacy comparable to supplements in low-phytate formulations.

Historical Context

Discovery and early recognition

The essentiality of zinc for biological growth was first demonstrated in 1869, when Jules Raulin showed that zinc was required for the proliferation of the fungus Aspergillus niger. Subsequent research established zinc as indispensable for plants in 1926 and for mammalian growth in rats by 1933, with deficiencies manifesting as impaired development and skin lesions in animal models. Early animal studies, such as those on swine parakeratosis in the 1930s and 1940s, linked low zinc intake to dermatological and growth disorders, though causal mechanisms were not fully elucidated until later biochemical analyses confirmed zinc's role in enzyme function. Human zinc deficiency was initially suspected in 1958 by Ananda S. Prasad, who evaluated a patient exhibiting severe alongside , prepubertal , , and (clay-eating), symptoms resembling those in multiple similar cases. In 1961, Prasad and colleagues published the first clinical description of zinc deficiency in humans, reporting on adolescent males in rural with "nutritional ," characterized by profound growth retardation, , , and low serum zinc levels attributable to diets high in phytate from , which inhibits zinc absorption. Zinc supplementation in these patients, combined with an omnivorous diet, resulted in rapid height gains of 12.7 to 15.2 cm within one year, alongside normalization of endocrine function and cessation of , providing direct evidence of . Further confirmation came in 1963, when Prasad's group detailed zinc abnormalities in these Iranian subjects, solidifying zinc's status as an essential human nutrient and highlighting dietary and absorptive factors in deficiency etiology. Early recognition also extended to genetic disorders; by 1973, Barnes and Moynahan identified —a condition with , alopecia, and —as stemming from severe zinc , responsive to supplementation. These findings shifted zinc from a presumed adequate dietary component to a critical , prompting the U.S. National Research Council to establish recommended dietary allowances in 1974.

Key research advancements

The recognition of zinc deficiency as a distinct clinical entity in humans emerged in 1963 through the work of Ananda S. Prasad, who documented cases of , , , and impaired taste acuity among adolescent males in rural and , attributing these to dietary zinc inadequacy exacerbated by high-phytate diets from . Supplementation with 30-45 mg of daily reversed growth stunting, normalized gonadal function, and restored taste perception within months, establishing zinc's essentiality for growth and reproduction. This breakthrough shifted zinc from an animal nutrient to a critical requirement, prompting global surveys that revealed widespread subclinical deficiency in developing regions. Subsequent advancements in the and included the formal establishment of recommended dietary allowances (RDAs) for by the U.S. , initially set at 15 mg/day for adult males based on balance studies and deficiency reversal data. Experimental models of marginal deficiency in healthy volunteers, conducted under controlled conditions with diets providing 3-5 mg daily, demonstrated dose-dependent effects such as reduced T-cell proliferation, thymic atrophy, and altered skin integrity after 12-24 weeks, underscoring 's role in without overt clinical disease. These studies quantified absorption inefficiencies from phytate-rich staples, informing interventions like fortification. Molecular insights advanced in the mid-1990s with the identification of two families of zinc transporters—SLC39 (ZIP) for influx and SLC30 (ZnT) for efflux—enabling precise mapping of intestinal absorption, cellular distribution, and mechanisms. This facilitated recognition of genetic disorders like as transporter defects, treatable with high-dose zinc. By the 2000s, randomized trials confirmed zinc's efficacy in reducing childhood duration by 25% and severity, leading to WHO guidelines for supplementation in deficient populations. Ongoing biomarker refinements, including erythrocyte and desaturation indices, addressed limitations of plasma zinc measurements, which fluctuate with and fail to detect marginal status in up to 20% of cases.

References

  1. https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3649098/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3724376/
  4. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0050568
  5. https://www.ncbi.nlm.nih.gov/books/NBK493231/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC7752109/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC7149581/
  8. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.717064/full
  9. https://bestpractice.bmj.com/topics/en-us/1195
  10. https://www.aafp.org/pubs/afp/issues/2009/0501/p768.html
  11. https://www.uptodate.com/contents/zinc-deficiency-and-supplementation-in-children
  12. https://my.clevelandclinic.org/health/diseases/zinc-deficiency
  13. https://www.mayocliniclabs.com/test-catalog/overview/7735
  14. https://www.labcorp.com/tests/001800/zinc-serum-or-plasma
  15. https://med.libretexts.org/Bookshelves/Nutrition/Principles_of_Nutritional_Assessment_3e_%28Gibson_et_al.%29/28%253A_Zinc_%28Chapter_24c%29/28.03%253A_New_Page
  16. https://www.cancerdiagnosisprognosis.org/storage/cdp/2/2/cdp-2-184.pdf
  17. https://nutritionalassessment.org/zinc/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC11224045/
  19. https://lpi.oregonstate.edu/mic/minerals/zinc
  20. https://www.tandfonline.com/doi/full/10.2147/IJGM.S476578
  21. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2021.700450/full
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC4446750/
  23. https://www.who.int/publications/m/item/WHO-WFP-UNICEF-statement-micronutrients-deficiencies-emergency
  24. https://www.researchgate.net/publication/342719639_Zinc_deficiency_in_low-_and_middle-income_countries_prevalence_and_approaches_for_mitigation
  25. https://onlinelibrary.wiley.com/doi/10.1111/jhn.12791
  26. https://globalnutritionreport.org/reports/2021-global-nutrition-report/assessing-progress-towards-the-global-nutrition-targets/
  27. https://www.ifpri.org/blog/addressing-global-life-long-health-impacts-zinc-deficiency-call-action/
  28. https://www.tandfonline.com/doi/full/10.1080/09637486.2025.2496954?src=exp-la
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC9556144/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC7699494/
  31. https://kidsnewtocanada.ca/care/zinc
  32. https://micronutrientforum.org/whats-in-a-number/
  33. https://www.sciencedirect.com/science/article/pii/S2161831324000152
  34. https://pubmed.ncbi.nlm.nih.gov/40288992/
  35. https://pubmed.ncbi.nlm.nih.gov/17988008/
  36. https://www.cambridge.org/core/journals/public-health-nutrition/article/basis-for-changes-in-the-disease-burden-estimates-related-to-vitamin-a-and-zinc-deficiencies-in-the-2017-and-2019-global-burden-of-disease-studies/0D3C57D1EF044BA7A1857E7D789F0134
  37. https://www.sciencedirect.com/science/article/pii/S0022316622140903
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC10882121/
  39. https://pubmed.ncbi.nlm.nih.gov/10801949/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC4231515/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC9313088/
  42. https://www.wjgnet.com/2150-5330/full/v5/i4/496.htm
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC10574543/
  44. https://www.mdpi.com/2072-6643/16/24/4269
  45. https://www.sciencedirect.com/science/article/pii/S2161831322011024
  46. https://www.gastrojournal.org/article/S0016-5085(09)01452-8/fulltext
  47. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/zinc-urine-level
  48. https://www.sciencedirect.com/science/article/pii/S0022316622140897
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC4175048/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC3681543/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC3868572/
  52. https://www.nature.com/articles/s41598-024-53202-0
  53. https://pubmed.ncbi.nlm.nih.gov/16819574/
  54. https://www.nature.com/articles/s41598-024-53202-0/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC6617024/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC4813198/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC2905048/
  58. https://immunityageing.biomedcentral.com/articles/10.1186/s12979-025-00511-1
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC9855948/
  60. https://www.ncbi.nlm.nih.gov/books/NBK441835/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC9887131/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC10561101/
  63. https://ijdvl.com/nails-in-nutritional-deficiencies/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC4120804/
  65. https://jamanetwork.com/journals/jamadermatology/article-abstract/548919
  66. https://rarediseases.org/rare-diseases/acrodermatitis-enteropathica/
  67. https://www.ncbi.nlm.nih.gov/books/NBK536929/
  68. https://link.springer.com/article/10.1007/s13670-024-00425-8
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC6685412/
  70. https://bmcoralhealth.biomedcentral.com/articles/10.1186/s12903-022-02088-3
  71. https://bmcoralhealth.biomedcentral.com/articles/10.1186/s12903-017-0450-x
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC7302722/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC7385976/
  74. https://www.sciencedirect.com/science/article/pii/S0946672X21001012
  75. https://www.researchgate.net/publication/45147716_Zinc_deficiency_may_be_a_cause_of_burning_mouth_syndrome_as_zinc_replacement_therapy_has_therapeutic_effects
  76. https://pmc.ncbi.nlm.nih.gov/articles/PMC10017214/
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC6957051/
  78. https://www.acpjournals.org/doi/10.7326/0003-4819-99-2-227
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC7883601/
  80. https://www.oatext.com/proposed-mechanism-for-anosmia-during-covid-19-the-role-of-local-zinc-distribution.php
  81. https://link.springer.com/article/10.1007/s12011-020-02546-5
  82. https://www.sciencedirect.com/science/article/pii/S0002916523066303
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC11250685/
  84. https://www.sciencedirect.com/science/article/pii/S1569199307001634
  85. https://pubmed.ncbi.nlm.nih.gov/38118309/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC6468114/
  87. https://link.springer.com/article/10.1007/BF00176533
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC5748737/
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC2277319/
  90. https://www.mdpi.com/2072-6643/9/12/1286
  91. https://www.sciencedirect.com/science/article/pii/S0022316622022611
  92. https://www.annualreviews.org/doi/10.1146/annurev-nutr-122019-120635
  93. https://today.uic.edu/zinc-deficiency-increases-risk-of-drug-resistant-pneumonia/
  94. https://pubmed.ncbi.nlm.nih.gov/37836377/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC7321011/
  96. https://badgut.org/information-centre/health-nutrition/zinc/
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC3506421/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC3715721/
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC7728061/
  100. https://www.sciencedirect.com/science/article/abs/pii/S0946672X12000740
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC3137935/
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC9312494/
  103. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1666887/full
  104. https://pubmed.ncbi.nlm.nih.gov/12730446/
  105. https://e-acnm.org/journal/view.php?doi=10.15747/ACNM.2024.16.3.112
  106. https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2013.00033/full
  107. https://www.jneurosci.org/content/41/13/3025
  108. https://www.mdpi.com/2072-6643/15/9/2140
  109. https://brieflands.com/articles/semj-13093
  110. https://www.who.int/tools/elena/bbc/zinc-stunting
  111. https://ajcn.nutrition.org/article/S0002-9165%2823%2906243-3/fulltext
  112. https://www.sciencedirect.com/science/article/pii/S0022316622141118
  113. https://pmc.ncbi.nlm.nih.gov/articles/PMC3453500/
  114. https://pubmed.ncbi.nlm.nih.gov/21501440/
  115. https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-11-S3-S22
  116. https://oamjms.eu/index.php/mjms/article/download/8022/6991
  117. https://bmcpediatr.biomedcentral.com/articles/10.1186/s12887-020-02340-1
  118. https://publications.aap.org/pediatrics/article/113/5/1297/66657/Cognitive-and-Motor-Development-Among-Small-for
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC6010824/
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC6027651/
  121. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.974443/full
  122. https://europepmc.org/article/med/549254
  123. https://pubmed.ncbi.nlm.nih.gov/6772723/
  124. https://pmc.ncbi.nlm.nih.gov/articles/PMC3040901/
  125. https://pmc.ncbi.nlm.nih.gov/articles/PMC10291914/
  126. https://www.nature.com/articles/srep22386
  127. https://www.mdpi.com/1422-0067/21/20/7796
  128. https://ovarianresearch.biomedcentral.com/articles/10.1186/s13048-024-01442-z
  129. https://www.sciencedirect.com/science/article/pii/S2405844024066362
  130. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0270971
  131. https://pmc.ncbi.nlm.nih.gov/articles/PMC8599883/
  132. https://www.sciencedirect.com/science/article/abs/pii/S0946672X22002048
  133. https://www.sciencedirect.com/science/article/abs/pii/S0301211525003586
  134. https://pmc.ncbi.nlm.nih.gov/articles/PMC7468694/
  135. https://www.droracle.ai/articles/133705/what-is-the-utility-in-obtaining-zinc-level
  136. https://www.mdpi.com/1422-0067/21/8/2941
  137. https://pmc.ncbi.nlm.nih.gov/articles/PMC4807640/
  138. https://pmc.ncbi.nlm.nih.gov/articles/PMC7138668/
  139. https://ltd.aruplab.com/Tests/Pub/0020097
  140. https://pubmed.ncbi.nlm.nih.gov/4078198/
  141. https://www.sciencedirect.com/science/article/pii/S0002916523238952
  142. https://pmc.ncbi.nlm.nih.gov/articles/PMC3142737/
  143. https://pmc.ncbi.nlm.nih.gov/articles/PMC8838617/
  144. https://www.merckmanuals.com/professional/nutritional-disorders/mineral-deficiency-and-toxicity/zinc-deficiency
  145. https://www.droracle.ai/articles/194504/dose-of-zinc-for-treatment
  146. https://www.who.int/tools/elena/interventions/zinc-diarrhoea
  147. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010386
  148. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009384.pub3/full
  149. https://pubmed.ncbi.nlm.nih.gov/36994923/
  150. https://pmc.ncbi.nlm.nih.gov/articles/PMC2874106/
  151. https://www.sciencedirect.com/science/article/abs/pii/S1043466620304129
  152. https://www.ncbi.nlm.nih.gov/books/NBK547698/
  153. https://pmc.ncbi.nlm.nih.gov/articles/PMC2820120/
  154. https://pmc.ncbi.nlm.nih.gov/articles/PMC9776731/
  155. https://pubmed.ncbi.nlm.nih.gov/26085547/
  156. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15749
  157. https://www.mayoclinicproceedings.org/article/S0025-6196%2811%2962239-8/fulltext
  158. https://www.ncbi.nlm.nih.gov/books/NBK554548/
  159. https://pmc.ncbi.nlm.nih.gov/articles/PMC11243279/
  160. https://www.mayoclinic.org/drugs-supplements-zinc/art-20366112
  161. https://www.sciencedirect.com/science/article/pii/S0022316622140927
  162. https://pubmed.ncbi.nlm.nih.gov/9701165/
  163. https://academic.oup.com/ajcn/article/68/2/484S/4648686
  164. https://jn.nutrition.org/article/S0022-3166%2822%2914092-7/fulltext
  165. https://pubmed.ncbi.nlm.nih.gov/19087462/
  166. https://www.sciencedirect.com/science/article/pii/S0022316622161560
  167. https://www.nature.com/articles/s43016-024-00997-w
  168. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010697.pub2
  169. https://pmc.ncbi.nlm.nih.gov/articles/PMC10262896/
  170. https://www.harvestplus.org/wp-content/uploads/2025/02/BiofortificationThe-Evidence.pdf
  171. https://austinpublishinggroup.com/nutrition-food-sciences/fulltext/ajnfs-v12-id1177.pdf
  172. https://www.sciencedirect.com/science/article/pii/S0022316624003493
  173. https://www.ifpri.org/blog/zinc-study-suggests-possible-role-biofortification-addressing-non-communicable-diseases/
  174. https://www.who.int/tools/elena/bbc/zinc-pneumonia-children
  175. https://www.emro.who.int/child-health/health-systems/example-of-policy-issue-zinc-supplementation.html
  176. https://www.izincg.org/
  177. https://www.zinc.org/lifesaving/
  178. https://crops.zinc.org/why-zinc/
  179. https://kochagronomicservices.com/knowledge-center/the-role-of-zinc-in-crop-production
  180. https://www.nature.com/articles/s41598-021-88304-6
  181. https://www.frontiersin.org/journals/soil-science/articles/10.3389/fsoil.2024.1421652/full
  182. http://nmsp.cals.cornell.edu/publications/factsheets/factsheet32.pdf
  183. https://www.sciencedirect.com/science/article/abs/pii/S0016706119323535
  184. https://pmc.ncbi.nlm.nih.gov/articles/PMC9586378/
  185. https://www.sciencedirect.com/science/article/pii/S2405844023032474
  186. https://www.frontiersin.org/journals/plant-science/articles/10.3389/fpls.2022.791066/full
  187. https://www.sciencedirect.com/science/article/abs/pii/S037842902200096X
  188. https://pmc.ncbi.nlm.nih.gov/articles/PMC8710766/
  189. https://pmc.ncbi.nlm.nih.gov/articles/PMC9638342/
  190. https://www.harvestplus.org/home/biofortification-why-and-how/
  191. https://www.cimmyt.org/news/twenty-years-of-enriching-diets-with-biofortification/
  192. https://www.harvestplus.org/crop/zinc-wheat/
  193. https://www.ifpri.org/blog/harvestplus-twenty-years-enriching-diets-biofortification/
  194. https://www.researchgate.net/figure/Zinc-rich-cereal-varieties-released-across-the-world_tbl1_391998257
  195. https://www.harvestplus.org/eating-zinc-biofortified-rice-modestly-improves-growth-of-young-children-research-finds/
  196. https://www.sciencedirect.com/science/article/pii/S2161831322010912
  197. https://ajcn.nutrition.org/article/S0002-9165%2823%2917108-5/abstract
  198. https://www.acpjournals.org/doi/10.7326/0003-4819-89-4-483
  199. https://www.jbc.org/article/S0021-9258%2821%2900090-9/fulltext
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.